Clinical Trial Search

Primary: Progression Free Survival (PFS) as Assessed by the Independent Radiology Review Committee (IRRC) — 12.1; 8.1 months — p=<0.0001

Primary: Number of Participants Requiring Post-procedural Opioid Analgesia Per Study Arm — 22; 22; 34; 34 participants

Primary: Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily…

Primary: Overall Survival (OS) — 14.29; 13.83; 13.17; 12.12 months — p=0.3629

Primary: Knowledge of Post Operative Opioids — 8.32; 9.36 units on a scale

Primary: Change From Baseline to Week 12 in Awake Objective Cough Frequency — -0.185; -0.192; -0.271; -0.243 coughs per hour (log transformed) — p=0.324

Primary: Average Heart Rate Over the Course of High-intensity Interval Exercise — 144; 143; 148; 149 beats per minute — p=0.003

Primary: Percentage of Participants Free From Radical Cystectomy at 3 Years — 88.2 percentage of participants

Primary: Difference Between AMR101 (Ethyl Icosapentate) and Placebo Treatment Groups in Triglyceride Lowering Effect — -5.6; -17.5; 5.9 Percent change from baseline — p=<0.0001

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms — 2; 5; 5; 3 Participants

Primary: Clinical Improvement by Day 14 — 61; 51; 18; 21 Participants — p=0.1854

Primary: Number of Participants Experiencing a Dose Limiting Toxicity (DLT) (Phase I) and the Recommended Phase IB Dose (RP2D) — 4; 4; 2 Participants

Primary: Stop Signal Task (SST) — 255; 215 milliseconds

Primary: Difference Between AMR101 (Ethyl Icosapentate) and Placebo Treatment Groups in Triglyceride Lowering Effect — -7.0; -26.6; 9.7 Percent change from baseline — p=<0.0001

Primary: Percentage of Participants With a State of Disease Control at Week 52 — 16.7; 19.4; 25.5 Percentage of participants — p=0.5342